National survey of pharmacists about coronary heart disease, hypercholesterolemia, nonprescription statin therapy, and pharmacists' services

James M. McKenney, J. Chris Bradberry, Robert L. Talbert, Edward Cahill, W. Virgil Brown

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: To determine the beliefs and attitudes of pharmacists about the significance of high blood cholesterol, coronary heart disease (CHD), nonprescription statin therapy for patients at moderate risk for CHD, and their role in support of cholesterol-lowering treatments in patients. Design: Cross-sectional survey. Setting: Nationwide sample of licensed pharmacists in ambulatory practice in the United States drawn randomly from databases of the American Pharmacists Association. Participants: 104 independent pharmacists and 169 chain pharmacists. Intervention: Web-based survey. Main Outcome Measure: Respondents' indication of strong agreement with questionnaire statements (selecting 8, 9, or 10 on a 10-point scale). Results: The survey found that 75% and 61% of pharmacists believed strongly that CHD and high blood cholesterol levels, respectively, are significant health problems facing Americans, and 60% believed that not enough is currently being done to reduce this risk. Pharmacists indicated that they very regularly advised patients about prescription and nonprescription treatments (75%) and encouraged adherence to them (78%); a smaller but substantial proportion regularly monitored patient response to prescription (33%) and nonprescription therapies (15%) and provided point-of-care cholesterol testing (7%). The survey also revealed that the majority of pharmacists (68%) would support consumers interested in purchasing a nonprescription statin product and 82% believed such a product would be more effective than currently available cholesterol-lowering dietary supplements. Pharmacists were concerned that patients pursuing nonprescription statins might discontinue their prescription cholesterol-lowering medications (79%), experience adverse effects (79%), and not be able to self-manage their use of a nonprescription statin product (78%). Conclusion: Community pharmacist members of APhA believe that CHD and cholesterol are important problems facing many people, routinely provide services that support patients who wish to self-administer nonprescription therapies, and would be interested in supporting consumers who wish to carry out therapy with a nonprescription statin.

Original languageEnglish (US)
Pages (from-to)562-568
Number of pages7
JournalJournal of the American Pharmacists Association
Volume44
Issue number5
DOIs
StatePublished - Jan 1 2004

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypercholesterolemia
Pharmacists
Coronary Disease
Cholesterol
Prescriptions
Blood
Therapeutics
Dietary supplements
Purchasing
Medical problems
Surveys and Questionnaires
Dietary Supplements
Testing
Cross-Sectional Studies
Outcome Assessment (Health Care)
Databases

All Science Journal Classification (ASJC) codes

  • Pharmacology (nursing)
  • Pharmacy
  • Pharmacology

Cite this

National survey of pharmacists about coronary heart disease, hypercholesterolemia, nonprescription statin therapy, and pharmacists' services. / McKenney, James M.; Bradberry, J. Chris; Talbert, Robert L.; Cahill, Edward; Virgil Brown, W.

In: Journal of the American Pharmacists Association, Vol. 44, No. 5, 01.01.2004, p. 562-568.

Research output: Contribution to journalArticle

@article{900772da9507492e8dd8b6cc88bcf889,
title = "National survey of pharmacists about coronary heart disease, hypercholesterolemia, nonprescription statin therapy, and pharmacists' services",
abstract = "Objective: To determine the beliefs and attitudes of pharmacists about the significance of high blood cholesterol, coronary heart disease (CHD), nonprescription statin therapy for patients at moderate risk for CHD, and their role in support of cholesterol-lowering treatments in patients. Design: Cross-sectional survey. Setting: Nationwide sample of licensed pharmacists in ambulatory practice in the United States drawn randomly from databases of the American Pharmacists Association. Participants: 104 independent pharmacists and 169 chain pharmacists. Intervention: Web-based survey. Main Outcome Measure: Respondents' indication of strong agreement with questionnaire statements (selecting 8, 9, or 10 on a 10-point scale). Results: The survey found that 75{\%} and 61{\%} of pharmacists believed strongly that CHD and high blood cholesterol levels, respectively, are significant health problems facing Americans, and 60{\%} believed that not enough is currently being done to reduce this risk. Pharmacists indicated that they very regularly advised patients about prescription and nonprescription treatments (75{\%}) and encouraged adherence to them (78{\%}); a smaller but substantial proportion regularly monitored patient response to prescription (33{\%}) and nonprescription therapies (15{\%}) and provided point-of-care cholesterol testing (7{\%}). The survey also revealed that the majority of pharmacists (68{\%}) would support consumers interested in purchasing a nonprescription statin product and 82{\%} believed such a product would be more effective than currently available cholesterol-lowering dietary supplements. Pharmacists were concerned that patients pursuing nonprescription statins might discontinue their prescription cholesterol-lowering medications (79{\%}), experience adverse effects (79{\%}), and not be able to self-manage their use of a nonprescription statin product (78{\%}). Conclusion: Community pharmacist members of APhA believe that CHD and cholesterol are important problems facing many people, routinely provide services that support patients who wish to self-administer nonprescription therapies, and would be interested in supporting consumers who wish to carry out therapy with a nonprescription statin.",
author = "McKenney, {James M.} and Bradberry, {J. Chris} and Talbert, {Robert L.} and Edward Cahill and {Virgil Brown}, W.",
year = "2004",
month = "1",
day = "1",
doi = "10.1331/1544-3191.44.5.562.McKenney",
language = "English (US)",
volume = "44",
pages = "562--568",
journal = "Journal of the American Pharmacists Association : JAPhA",
issn = "1544-3191",
publisher = "American Pharmacists Association",
number = "5",

}

TY - JOUR

T1 - National survey of pharmacists about coronary heart disease, hypercholesterolemia, nonprescription statin therapy, and pharmacists' services

AU - McKenney, James M.

AU - Bradberry, J. Chris

AU - Talbert, Robert L.

AU - Cahill, Edward

AU - Virgil Brown, W.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Objective: To determine the beliefs and attitudes of pharmacists about the significance of high blood cholesterol, coronary heart disease (CHD), nonprescription statin therapy for patients at moderate risk for CHD, and their role in support of cholesterol-lowering treatments in patients. Design: Cross-sectional survey. Setting: Nationwide sample of licensed pharmacists in ambulatory practice in the United States drawn randomly from databases of the American Pharmacists Association. Participants: 104 independent pharmacists and 169 chain pharmacists. Intervention: Web-based survey. Main Outcome Measure: Respondents' indication of strong agreement with questionnaire statements (selecting 8, 9, or 10 on a 10-point scale). Results: The survey found that 75% and 61% of pharmacists believed strongly that CHD and high blood cholesterol levels, respectively, are significant health problems facing Americans, and 60% believed that not enough is currently being done to reduce this risk. Pharmacists indicated that they very regularly advised patients about prescription and nonprescription treatments (75%) and encouraged adherence to them (78%); a smaller but substantial proportion regularly monitored patient response to prescription (33%) and nonprescription therapies (15%) and provided point-of-care cholesterol testing (7%). The survey also revealed that the majority of pharmacists (68%) would support consumers interested in purchasing a nonprescription statin product and 82% believed such a product would be more effective than currently available cholesterol-lowering dietary supplements. Pharmacists were concerned that patients pursuing nonprescription statins might discontinue their prescription cholesterol-lowering medications (79%), experience adverse effects (79%), and not be able to self-manage their use of a nonprescription statin product (78%). Conclusion: Community pharmacist members of APhA believe that CHD and cholesterol are important problems facing many people, routinely provide services that support patients who wish to self-administer nonprescription therapies, and would be interested in supporting consumers who wish to carry out therapy with a nonprescription statin.

AB - Objective: To determine the beliefs and attitudes of pharmacists about the significance of high blood cholesterol, coronary heart disease (CHD), nonprescription statin therapy for patients at moderate risk for CHD, and their role in support of cholesterol-lowering treatments in patients. Design: Cross-sectional survey. Setting: Nationwide sample of licensed pharmacists in ambulatory practice in the United States drawn randomly from databases of the American Pharmacists Association. Participants: 104 independent pharmacists and 169 chain pharmacists. Intervention: Web-based survey. Main Outcome Measure: Respondents' indication of strong agreement with questionnaire statements (selecting 8, 9, or 10 on a 10-point scale). Results: The survey found that 75% and 61% of pharmacists believed strongly that CHD and high blood cholesterol levels, respectively, are significant health problems facing Americans, and 60% believed that not enough is currently being done to reduce this risk. Pharmacists indicated that they very regularly advised patients about prescription and nonprescription treatments (75%) and encouraged adherence to them (78%); a smaller but substantial proportion regularly monitored patient response to prescription (33%) and nonprescription therapies (15%) and provided point-of-care cholesterol testing (7%). The survey also revealed that the majority of pharmacists (68%) would support consumers interested in purchasing a nonprescription statin product and 82% believed such a product would be more effective than currently available cholesterol-lowering dietary supplements. Pharmacists were concerned that patients pursuing nonprescription statins might discontinue their prescription cholesterol-lowering medications (79%), experience adverse effects (79%), and not be able to self-manage their use of a nonprescription statin product (78%). Conclusion: Community pharmacist members of APhA believe that CHD and cholesterol are important problems facing many people, routinely provide services that support patients who wish to self-administer nonprescription therapies, and would be interested in supporting consumers who wish to carry out therapy with a nonprescription statin.

UR - http://www.scopus.com/inward/record.url?scp=85047688410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047688410&partnerID=8YFLogxK

U2 - 10.1331/1544-3191.44.5.562.McKenney

DO - 10.1331/1544-3191.44.5.562.McKenney

M3 - Article

C2 - 15496041

AN - SCOPUS:85047688410

VL - 44

SP - 562

EP - 568

JO - Journal of the American Pharmacists Association : JAPhA

JF - Journal of the American Pharmacists Association : JAPhA

SN - 1544-3191

IS - 5

ER -